We are live on ! Find out more
CALA

Calithera Biosciences, Inc

Delisted

CALA was delisted on the 1st of February, 2023.

66 hedge funds and large institutions have $100M invested in Calithera Biosciences, Inc in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 23 increasing their positions, 22 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

273% more call options, than puts

Call options by funds: $1.23M | Put options by funds: $330K

5% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 22

1% more capital invested

Capital invested by funds: $98.5M → $100M (+$1.47M)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

13% less funds holding

Funds holding: 7666 (-10)

60% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 15

Holders
66
Holders Change
-10
Holders Change %
-13.16%
% of All Funds
1.16%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
6
Increased
23
Reduced
22
Closed
15
Calls
$1.23M
Puts
$330K
Net Calls
+$900K
Net Calls Change
-$71K
Name Holding Trade Value Shares
Change
Change in
Stake
Acadian Asset Management
26
Acadian Asset Management
Massachusetts
$339K +$249K +5,769 +285%
Northern Trust
27
Northern Trust
Illinois
$334K +$65.9K +1,528 +25%
FSA
28
Franklin Street Advisors
North Carolina
$291K +$259 +6 +0.1%
Franklin Resources
29
Franklin Resources
California
$290K +$287K +6,660 New
HF
30
HRT Financial
New York
$282K -$131K -3,040 -32%
GC
31
Grimes & Company
Massachusetts
$251K +$8.63K +200 +4%
PHP
32
Parkman Healthcare Partners
Connecticut
$219K
Two Sigma Advisers
33
Two Sigma Advisers
New York
$185K +$14K +325 +8%
Goldman Sachs
34
Goldman Sachs
New York
$152K -$288K -6,670 -66%
D.E. Shaw & Co
35
D.E. Shaw & Co
New York
$113K -$15.1K -350 -12%
Group One Trading
36
Group One Trading
Illinois
$106K -$17K -394 -14%
Charles Schwab
37
Charles Schwab
California
$102K +$49.5K +1,148 +98%
Morgan Stanley
38
Morgan Stanley
New York
$85K -$2.04M -47,326 -96%
Bank of America
39
Bank of America
North Carolina
$82K -$135K -3,126 -62%
Bank of New York Mellon
40
Bank of New York Mellon
New York
$68K
ECM
41
ExodusPoint Capital Management
New York
$67K -$98.9K -2,292 -60%
Tudor Investment Corp
42
Tudor Investment Corp
Connecticut
$59K +$58.1K +1,347 New
TCA
43
Transcend Capital Advisors
New Jersey
$57K +$21.6K +500 +51%
TRCT
44
Tower Research Capital (TRC)
New York
$53K +$7.81K +181 +18%
KAS
45
Kestra Advisory Services
Texas
$44K
XT
46
XTX Topco
Cayman Islands
$40K -$27.8K -645 -41%
VF
47
Virtu Financial
New York
$39K +$38.4K +889 New
SAM
48
Seelaus Asset Management
New Jersey
$35K
ProShare Advisors
49
ProShare Advisors
Maryland
$35K +$5.48K +127 +19%
FCA
50
FinTrust Capital Advisors
South Carolina
$29K +$16.2K +375 +133%

CALA Hedge Fund Activity: Q3 2021 in Review

66 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Calithera Biosciences, Inc (CALA) for Q3 2021, worth a combined $100M — up 1.5% from $98.5M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of CALA and 6 opened new positions — a net loss of 9 holders — while 22 trimmed existing stakes and 23 added.

The largest buyer was Citadel Advisors, adding an estimated $2.22M. The largest seller was Adage Capital Partners, cutting an estimated $3.99M.

  • 66 institutional investors held Calithera Biosciences, Inc (CALA) as of Q3 2021, down from 76 in Q2 2021.
  • Funds reported $100M of Calithera Biosciences, Inc stock for Q3 2021, up 1.5% quarter-over-quarter.
  • 6 funds opened new Calithera Biosciences, Inc positions in Q3 2021 and 15 closed out, a net change of -9 holders.
  • The largest Calithera Biosciences, Inc buyer in Q3 2021 was Citadel Advisors, an estimated $2.22M added.
  • The largest Calithera Biosciences, Inc seller in Q3 2021 was Adage Capital Partners, an estimated $3.99M sold.

Based on aggregated 13F filings for Q3 2021.